Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Asymchem Laboratories (Tianjin) Co., Ltd. Class H ( (HK:6821) ) has issued an announcement.
Asymchem Laboratories (Tianjin) Co., Ltd. has scheduled a board meeting for 30 March 2026 to review and approve the annual results of the company and its subsidiaries for the financial year ended 31 December 2025. The board will also consider the recommendation of a final dividend, signaling a potential distribution of profits to shareholders, subject to approval.
The announcement confirms the current composition of the board, led by Chairperson and CEO Dr. Hao Hong, alongside executive, non-executive, and independent non-executive directors, underscoring the company’s established governance structure. The upcoming results review and dividend consideration may provide investors with fresh insight into the company’s recent financial performance and capital-return intentions.
The most recent analyst rating on (HK:6821) stock is a Hold with a HK$90.00 price target. To see the full list of analyst forecasts on Asymchem Laboratories (Tianjin) Co., Ltd. Class H stock, see the HK:6821 Stock Forecast page.
More about Asymchem Laboratories (Tianjin) Co., Ltd. Class H
Asymchem Laboratories (Tianjin) Co., Ltd. is a China-incorporated joint stock company listed in Hong Kong, operating in the pharmaceutical and life sciences sector. The company focuses on laboratory-based services and solutions, supporting drug development and related activities for clients in the healthcare and biopharmaceutical markets.
Average Trading Volume: 306,272
Technical Sentiment Signal: Buy
Current Market Cap: HK$39.58B
For detailed information about 6821 stock, go to TipRanks’ Stock Analysis page.